Home / Petrochemicals / EpiCast Report: Hemophilia - Epidemiology Forecast to 2024

EpiCast Report: Hemophilia - Epidemiology Forecast to 2024

Published: Oct 2015 | No Of Pages: 46 | Published By: GlobalData

EpiCast Report: Hemophilia - Epidemiology Forecast to 2024

Summary

Hemophilia is an X-linked hereditary bleeding disorder, characterized by impaired blood coagulation as a result of deficiencies in the production or function of coagulation factor VIII (hemophilia A) or factor IX (hemophilia B). Because of the deficiency of coagulation factor, hemophilia patients have a tendency for bleeding in joints, muscles, soft tissues, and within mucous membranes, which can be either spontaneous or due to internal or external trauma, depending on the severity of the disease.

In 2014, the 9MM had 60,671 diagnosed prevalent cases of hemophilia A and hemophilia B, around 28% of which occurred in the US. The diagnosed prevalent cases of hemophilia in the 9MM are expected to increase slightly to 61,954 cases by 2024. The US will have the largest proportion of diagnosed prevalent cases of hemophilia A and hemophilia B in the 9MM in 2024 at 29.05%. Because hemophilia is an inherited condition, it requires lifelong treatment. Given the increase in the prevalence of hypertension, with advancing age and increasing life expectancy in hemophiliacs due to advances in treatment, the challenges faced by hemophiliacs and the need for more supportive treatments and care will increase in the near future.

GlobalData epidemiologists forecast the epidemiological trend for hemophilia using data from the WFH Annual Global Survey Report, which is considered the gold standard for hemophilia data. The World Health Organization (WHO) authenticates the WFH data for hemophilia and other bleeding disorders and provides the most accurate data possible for hemophilia globally. The WFH Global Survey Report uses uniform data collection methods for each national member organization (NMO), allowing for a meaningful comparison of the diagnosed prevalent cases across the markets. A major strength of this analysis lays in the use of country-specific data and a uniform methodology across the markets to forecast the prevalent cases of hemophilia.

Scope

- The Hemophilia EpiCast Report provides an overview of the risk factors and global trends of hemophilia in the 9MM (US, France, Germany, Italy, Spain, UK, Japan, Argentina, and China). In addition, the report includes a 10-year epidemiological forecast of the diagnosed prevalent cases of hemophilia, segmented by type (A and B), sex, and age (starting at ages 0 years) in these markets.
- The hemophilia epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 9MM.

Reasons to buy

The Hemophilia EpiCast report will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global hemophilia market.
- Quantify patient populations in the global hemophilia market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for hemophilia therapeutics in each of the markets covered.
- Identify the hemophilia type that is most important to your marketing plans.

1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 6
2 Introduction 7
2.1 Catalyst 7
2.2 Related Reports 8
2.3 Upcoming Related Reports 8
3 Epidemiology 9
3.1 Disease Background 9
3.2 Risk Factors and Comorbidities 10
3.3 Global Trends 11
3.4 Forecast Methodology 13
3.4.1 Sources Used 13
3.4.2 Sources Not Used 14
3.4.3 Forecast Assumptions and Methods 15
3.5 Epidemiological Forecast for Hemophilia A (2014-2024) 19
3.5.1 Diagnosed Prevalent Cases of Hemophilia A 19
3.5.2 Diagnosed Prevalent Cases of Hemophilia A by Age 20
3.5.3 Diagnosed Prevalent Cases of Hemophilia A by Sex 22
3.5.4 Age-Standardized Diagnosed Prevalence of Hemophilia A 24
3.6 Epidemiological Forecast for Hemophilia B (2014-2024) 26
3.6.1 Diagnosed Prevalent Cases of Hemophilia B 26
3.6.2 Diagnosed Prevalent Cases of Hemophilia B by Age 27
3.6.3 Diagnosed Prevalent Cases of Hemophilia B by Sex 29
3.6.4 Age-Standardized Diagnosed Prevalence of Hemophilia B 31
3.7 Epidemiological Forecast for Hemophilia A and Hemophilia B (2014-2024) 32
3.7.1 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B 32
3.7.2 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Sex 34
3.8 Discussion 36
3.8.1 Conclusions on Epidemiological Trends 36
3.8.2 Limitations of the Analysis 37
3.8.3 Strengths of the Analysis 38
4 Appendix 39
4.1 Bibliography 39
4.2 About the Authors 41
4.2.1 Epidemiologists 41
4.2.2 Reviewers 42
4.2.3 Global Director of Epidemiology and Health Policy 42
4.2.4 Global Head of Healthcare 43
4.3 About GlobalData 44
4.4 About EpiCast 44
4.5 Disclaimer 45

1.1 List of Tables
Table 1: Relationship of Bleeding Severity with Clotting Factor Level 9
Table 2: Hemophilia - Risk Factors and Comorbidities 11
Table 3: 9MM, Diagnosed Prevalence of Hemophilia A (per 100,000 Population), Both Sexes, All Ages, 2004-2013 12
Table 4: 9MM, Diagnosed Prevalence of Hemophilia B (per 100,000 Population), Both Sexes, All Ages, 2004-2013 12
Table 5: 9MM, Sources and Diagnosed Prevalence Data for Hemophilia A and B 13
Table 6: 9MM, Diagnosed Prevalent Cases of Hemophilia A, Both Sexes, All Ages, N, 2014-2024 19
Table 7: 9MM, Diagnosed Prevalent Cases of Hemophilia A, Both Sexes, by Age, N, Row (%), 2014 21
Table 8: 9MM, Diagnosed Prevalent Cases of Hemophilia A, by Sex, All Ages, N, Row (%), 2014 23
Table 9: 9MM, Diagnosed Prevalent Cases of Hemophilia B, Both Sexes, All Ages, N, 2014-2024 26
Table 10: 9MM, Diagnosed Prevalent Cases of Hemophilia B, Both Sexes, by Age, N, Row (%), 2014 28
Table 11: 9MM, Diagnosed Prevalent Cases of Hemophilia B, by Sex, All Ages, N, Row (%), 2014 30
Table 12: 9MM, Diagnosed Prevalent Cases of Hemophilia, Both Sexes, All Ages, N, 2014-2024 33
Table 13: 9MM, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, by Sex, All Ages, N, Row (%), 2014 35

1.2 List of Figures
Figure 1: 9MM, Diagnosed Prevalent Cases of Hemophilia A, Both Sexes, All Ages, N, 2014-2024 20
Figure 2: 9MM, Diagnosed Prevalent Cases of Hemophilia A, Both Sexes, by Age, N, 2014 22
Figure 3: 9MM, Diagnosed Prevalent Cases of Hemophilia A, by Sex, All Ages, N, 2014 24
Figure 4: 9MM, Age-Standardized Diagnosed Prevalence of Hemophilia A (per 100,000 Population), by Sex, 2014 25
Figure 5: 9MM, Diagnosed Prevalent Cases of Hemophilia B, Both Sexes, All Ages, N, 2014-2024 27
Figure 6: 9MM, Diagnosed Prevalent Cases of Hemophilia B, Both Sexes, by Age, N, 2014 29
Figure 7: 9MM, Diagnosed Prevalent Cases of Hemophilia B, by Sex, All Ages, N, 2014 31
Figure 8: 9MM, Age-Standardized Prevalence of Diagnosed Hemophilia B (per 100,000 Population), by Sex, 2014 32
Figure 9: 9MM, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, Both Sexes, All Ages, N, 2014-2024 34
Figure 10: 9MM, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, by Sex, All Ages, N, 2014 36

Choose License Type
 
Contact Information
24/7 Research Support
Phone: +1-855-455-8662
sales@acutemarketreports.com
Get in Touch with us
join us on Facebook
Follow us on Twitter
Follow us on LinkedIn
Add us on Google +